In a recent internal meeting, Giovanni Caforio, the CEO of Bristol Myers Squibb, directly challenged the company's senior managers to reconsider their approach to drug development and operational efficiency.
Caforio questioned why the company was not moving faster on promising pipeline assets and urged executives to adopt a more agile mindset. He emphasized the need to reduce bureaucratic delays and streamline decision-making processes across the organization.
The CEO also highlighted the importance of focusing on patient outcomes rather than internal metrics alone. He called for greater collaboration between research teams and commercial teams to accelerate the delivery of new therapies to market.
This push comes as Bristol Myers Squibb faces increasing pressure from investors to improve its stock performance and deliver on its long-term growth strategy. The company reported mixed results in its latest quarterly earnings, with some key drugs missing revenue expectations.
Caforio's challenge reflects a broader trend among pharmaceutical leaders to modernize operations and respond more quickly to evolving market demands and regulatory environments.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing